METHODS OF USE OF SECRETORY IgA
US-2016318994-A1 · Nov 3, 2016 · US
US10696734B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10696734-B2 |
| Application number | US-201615249811-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 29, 2016 |
| Priority date | Jan 4, 2013 |
| Publication date | Jun 30, 2020 |
| Grant date | Jun 30, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Described herein is secretory IgA isolated from the intestinal luminal fluid and intestinal mucosal of animals such as pigs and cows. Also included are methods of isolating secretory IgA. The secretory IgA is useful in food compositions such as animal and human food compositions as well as pharmaceutical compositions to increase growth rate, improve feed efficiency, reduce gastrointestinal inflammation, reduce a risk of gastrointestinal infection in the animal, or a combination thereof.
Opening claim text (preview).
The invention claimed is: 1. A composition comprising pure, pasteurized secretory IgA isolated from intestinal luminal fluid or intestinal mucosa of a pig or a cow, wherein the pure, pasteurized SIgA composition has an E. coli 055:B5 lipopolysaccharide binding activity at least 5 times greater than pig or cow serum IgA E. coli 055:B5 lipopolysaccharide binding activity. 2. The composition of claim 1 , wherein the pure secretory IgA is greater than 75% pure. 3. The composition of claim 1 , in the form of a pharmaceutical composition further comprising a pharmaceutically acceptable excipient. 4. A composition comprising secretory IgA isolated from a source that is intestinal mucosa of a pig or a cow, wherein the concentration of secretory IgA in the isolated secretory IgA is at least twice the concentration in the source material, wherein the source material is dried intestinal mucosa, an aqueous preparation from intestinal mucosa, or a dry preparation of proteins prepared from intestinal mucosa, wherein the secretory IgA is pasteurized, wherein the pure, pasteurized SIgA composition has an E. coli 055:B5 lipopolysaccharide binding activity at least 5 times greater than pig or cow serum IgA E. coli 055:B5 lipopolysaccharide binding activity. 5. The composition of claim 4 , wherein greater than 5% of the protein in the isolated secretory IgA comprises IgA. 6. The method of claim 1 , wherein pasteurization is at 50-100° C. for 30 seconds. 7. The method of claim 1 , wherein pasteurization is at 120-150° C. for 1-8 seconds. 8. The method of claim 4 , wherein pasteurization is at 50-100° C. for 30 seconds. 9. The method of claim 4 , wherein pasteurization is at 120-150° C. for 1-8 seconds.
for poultry · CPC title
against material from animals or humans · CPC title
for aquatic animals, e.g. fish, crustaceans or molluscs · CPC title
characterized by taxonomic origin · CPC title
for horses · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.